Summit Therapeutics (SMMT) Total Liabilities (2017 - 2026)

Summit Therapeutics (SMMT) has 10 years of Total Liabilities data on file, last reported at $122.2 million in Q2 2026.

• Quarterly Total Liabilities rose 89.17% year-over-year to $122.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $122.2 million (up 89.17% YoY) and the FY2025 annual result came in at $92.3 million, up 97.22% from the prior year.
• Total Liabilities improved to $122.2 million in Q2 2026, from $101.9 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $537.5 million in Q4 2022 to a low of $22.1 million in Q3 2022.
• A 5-year average of $112.3 million and a median of $97.1 million in 2025 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities soared 1686.35% — and 2023, when it slumped 76.7%.
• Tracing SMMT's Total Liabilities over 5 years: stood at $537.5 million in 2022, then tumbled by 76.7% to $125.3 million in 2023, then plunged by 62.63% to $46.8 million in 2024, then soared by 97.22% to $92.3 million in 2025, then soared by 32.36% to $122.2 million in 2026.
• The last three Total Liabilities figures came in at $122.2 million (Q2 2026), $101.9 million (Q1 2026), and $92.3 million (Q4 2025), per Business Quant data.